Evidence map›Paper›PMID 31878945›Full record

ArticleCell communication and signaling : CCS2019

Cholesterol restricts lymphotoxin β receptor-triggered NF-κB signaling.

Magdalena Banach-Orłowska, Renata Wyszyńska, Beata Pyrzyńska, Małgorzata Maksymowicz, Jakub Gołąb, Marta Miączyńska

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. CREB1 Transcriptionally Activates LTBR to Promote the NF-Computational and mathematical methods in medicine · 2022
    Article
  8. Effects of Statins on Renin-Angiotensin System.Journal of cardiovascular development and disease · 2021
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Magdalena Banach-OrłowskaLaboratory of Cell Biology, International Institute of Molecular and Cell Biology, 02-109, Warsaw, Poland. magre@iimcb.gov.pl.ORCID 0000-0003-0617-109X
Renata WyszyńskaLaboratory of Cell Biology, International Institute of Molecular and Cell Biology, 02-109, Warsaw, Poland.
Beata PyrzyńskaDepartment of Immunology, Medical University of Warsaw, Warsaw, Poland.
Małgorzata MaksymowiczLaboratory of Cell Biology, International Institute of Molecular and Cell Biology, 02-109, Warsaw, Poland.
Jakub GołąbDepartment of Immunology, Medical University of Warsaw, Warsaw, Poland.
Marta MiączyńskaLaboratory of Cell Biology, International Institute of Molecular and Cell Biology, 02-109, Warsaw, Poland.
International Institute of Molecular and Cell Biology · PLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphotoxin β receptor (LTβR) plays important roles in the development of the immune system and immune response. At the cellular level, ligand-bound LTβR activates the pro-inflammatory NF-κB pathway but the detailed mechanisms regulating its signaling remain unknown. Understanding them is of high importance since LTβR and its ligands are promising therapeutic targets. Here, we studied the consequences of perturbed cellular cholesterol content on LTβR-induced NF-κB signaling.

methodsTo modulate cholesterol availability and/or level in lung carcinoma A549 and H2228, and endothelial HUVEC cells different treatment regimens with filipin, methyl-β-cyclodextrin and simvastatin were applied. LTβR localization was studied by confocal microscopy. The activity of LTβR-induced NF-κB pathway was assessed by measuring the levels of NF-κB pathway inhibitor IκBα and phosphorylation of RelA transcription factor by Western blotting. The NF-κB transcriptional response, production of chemokines and adhesion molecules were examined by qRT-PCR, ELISA, and Western blotting, respectively. Adherence of different types of primary immune cells to epithelial A549 cells and endothelial HUVECs was measured fluorometrically. Interactions of LTβR with its protein partners were investigated by immunoprecipitation.

resultsWe showed that filipin-mediated sequestration of cholesterol or its depletion from the plasma membrane with methyl-β-cyclodextrin impaired LTβR internalization and potentiated LTβR-dependent activation of the canonical branch of the NF-κB pathway. The latter was manifested by enhanced degradation of IκBα inhibitor, elevated RelA phosphorylation, substantial increase in the expression of NF-κB target genes encoding, among others, cytokines and adhesion molecules known to play important roles in immune response. It was followed by robust secretion of CXCL8 and upregulation of ICAM1, that favored the adhesion of immune cells (NK and T cells, neutrophils) to A549 cells and HUVECs. Mechanistically, we showed that cholesterol depletion stabilized interactions of ligand-stimulated LTβR with modified forms of TRAF2 and NEMO proteins.

conclusionsOur results showed that the reduction of the plasma membrane content of cholesterol or its sequestration strongly potentiated signaling outcome initiated by LTβR. Thus, drugs modulating cholesterol levels could potentially improve efficacy of LTβR-based therapies. Video abstract.

Indexed as

A549 CellsCells, CulturedCholesterolHumansJurkat CellsLymphotoxin beta ReceptorNeutrophilsNF-kappa BSignal TransductionCholesterolLTBR protein, humanLymphotoxin beta ReceptorNF-kappa BCholesterolLymphotoxin β receptorNEMONF-κB signalingReceptor internalizationTRAF2

Identifiers

PMID31878945
PMCPMC6933913
OpenAlexW2998043919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.